TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04376216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 60 mg with dose tapering over 2 months
Study: NCT04125043

Intervention type: DIAGNOSTIC_TEST
Intervention: Direct ophthalmoscope
Description: Red reflex test
Study: NCT04325893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: First dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TFirst dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. The treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.
Study: NCT02447965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Using ultrasound guidance bupivacaine will be injected into the active group's rectus abdominis sheath.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Using ultrasound guidance normal saline will be injected into the placebo group's rectus abdominis sheath.
Study: NCT02707068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Of LIfe Tool for IBD (QOLITI)
Description: The cognitive-behavioural therapy (CBT)-inspired manual will contain several chapters each of which addresses a different topic with information, guidance in setting goals for behaviour change and accompanying tasks to aid implementation which will be completed at home in the participant's own time. Key themes are likely to include symptom management, dealing with social implications of the disease and interacting effectively with healthcare professionals among others. Each chapter will address a theme providing information, sign posting to appropriate organisations, step-by-step tasks and quotes from pwIBD among others, drawing on relevant therapeutic approaches for self-management including CBT and certain elements of Acceptance and Commitment Therapy.
Study: NCT02913482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Risdiplam will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Risdiplam will be administered orally.
Study: NCT03061071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NightBalance Sleep Position Trainer (SPT)
Description: Subject to sleep with the SPT for a 6 week home use period followed by in-lab PSG.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NightBalance Sleep Position Trainer (SPT)
Description: Subject to sleep with the SPT for a 6 week home use period followed by in-lab PSG.
Study: NCT03806621

Intervention type: PROCEDURE
Intervention: Rotational Atherectomy
Description: Patients with severe calcified lesions will receive rotational atherectomy during index PCI
Study: NCT02186613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone support
Description: Telephone support intervention to improve breastfeeding rates. The intervention will consist in weekly calls during the first two months and every two weeks between the second and the sixth month. The intervention will be done by pediatric nurses and we have developed a protocol of important issues to deal depending on the age of the baby.
Study: NCT03061071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Adjusting Positive Airway Pressure (APAP)
Description: Subject to sleep with the APAP for a 6 week home use period followed by in-lab PSG.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Adjusting Positive Airway Pressure (APAP)
Description: Subject to sleep with the APAP for a 6 week home use period followed by in-lab PSG.
Study: NCT03143530

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pectoralis block
Description: Pectoralis block involving injection near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior muscles (pecs II).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pectoralis block
Description: Pectoralis block involving injection near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior muscles (pecs II).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline injection
Description: Pectoralis block involving injection of normal saline 30ml near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Injection
Description: Pectoralis block involving injection of ropivacaine injection 30ml of 0,25% (75 mg) near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
Study: NCT01929590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-3350 group 2
Description: split-dose (PEG-3350; 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-3350 group 1
Description: PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-3350 group 3
Description: low-volume 2 L PEG-solution (same day of the procedure 06:00-08:00 am)
Study: NCT00687401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6 (induction phase), and 14 (maintenance phase).
Study: NCT03178435

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measures to prevent AKI among critically ill patients
Description: 1. Meticulous optimization of the fluid balance~2. Avoidance of nephrotoxic medications where possible~3. Optimisation of the hemodynamic status~4. Avoidance of blood transfusion unless marked acute blood loss or symptomatic anemia~5. Optimization of the underlying medical condition~6. Seek expert renal advise when necessary
Study: NCT03703778

Intervention type: PROCEDURE
Intervention: Androgen deprivation therapy - bilateral orchidectomy
Description: Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.

Intervention type: DRUG
Intervention: Androgen deprivation therapy - GnRH agonist
Description: Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.

Intervention type: DRUG
Intervention: Androgen deprivation therapy - GnRH antagonist
Description: Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
Study: NCT02230566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX003
Description: UX003 is a sterile concentrate formulation of rhGUS for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX003
Description: UX003 is a sterile concentrate formulation of rhGUS for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX003
Description: UX003 is a sterile concentrate formulation of rhGUS for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX003
Description: UX003 is a sterile concentrate formulation of rhGUS for intravenous infusion
Study: NCT01981473

Intervention type: OTHER
Intervention: no intervention
Study: NCT02230566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo consisting of the UX003 formulation buffer (without rhGUS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo consisting of the UX003 formulation buffer (without rhGUS)
Study: NCT01981473

Intervention type: OTHER
Intervention: no intervention

Intervention type: OTHER
Intervention: no intervention
Study: NCT03368339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PR013 (0.045%)
Description: PR013 topical Ophthalmic Drops (0.045%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PR013 (0.06%)
Description: PR013 topical Ophthalmic Drops (0.06%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle
Study: NCT02230566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo consisting of the UX003 formulation buffer (without rhGUS)
Study: NCT00809601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of a specific type of ventilation tube through the tympanic membrane
Description: The ventilation tubes are tested using one type in one ear and another type as an active comparator in the other ear.~The investigators will test in total 4 different kinds of tubes. Four different combinations of tubes will be tested.~The first combination will test:~Shepard tube (double flanged, Fluoroplastic) vs Donaldson tube (double flanged, silicone)~The second combination will test:~Straight tube (single flanged, Fluoroplastic) vs Armstrong (single flanged, silicone)~The third combination will test:~Armstrong (single flanged, silicone) vs Donaldson tube (double flanged, silicone)~The fourth combination will test:~Straight tube (single flanged, Fluoroplastic) vs Shepard tube (double flanged, Fluoroplastic)
Study: NCT02436590

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthofix Physio-Stim Model 3315OA
Description: Active device emits PEMF signal; placebo/control device does not emit PEMF signal

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Orthofix Physio-Stim Model 3315OA
Description: Active device emits PEMF signal; placebo/control device does not emit PEMF signal
Study: NCT01119599

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3-D conformal radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO
Study: NCT04183114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles-Rubella vaccine Bio Farma
Description: MR vaccine produced by Bio Frama with 3 consecutive batches

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles-Rubella vaccine Bio Farma
Description: MR vaccine produced by Bio Frama with 3 consecutive batches
Study: NCT01119599

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study: NCT04183114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles-Rubella vaccine Bio Farma
Description: MR vaccine produced by Bio Frama with 3 consecutive batches

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MR Vaccine SII
Description: MR Vaccine produced by SII (Already registered in Indonesia)
Study: NCT03798613

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apple Watch 4 Series Device
Description: tracings from the apple watch 4 series watch

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Telemetry Monitor
Description: tracings from the continuous telemetry monitor
Study: NCT03306966

Intervention type: DEVICE
Intervention: Endoscopic Linear Cutter Stapler and Reloads (Frankenman)
Description: The Single Use Endoscopic Linear Cutter Stapler and Reloads from Frankenman received CE-mark in April 2013. It is used to staple and simultaneously divide tissue from the central line.
Study: NCT00184223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: 2 sessions of 45 minutes each with manual guided motivational interviewing delivered individually by a trained therapist.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual is individualized according to the clinical condition of the patients during the stay and in accordance with general national and international medical standards. It includes detoxification, pharmacotherapy, and general psychotherapy. Also, treatment is given for any coexisting non-substance-related disorder, including psychiatric disorders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual is individualized according to the clinical condition of the patients during the stay and in accordance with general national and international medical standards. It includes detoxification, pharmacotherapy, and general psychotherapy. Also, treatment is given for any coexisting non-substance-related disorder, including psychiatric disorders.
Study: NCT01655758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% timolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol-dorzolamide fixed combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost
Study: NCT01119599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01655758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost
Study: NCT01119599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT03246776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halometasone Triclosan
Description: Halometasone Triclosan . The study product will be applied topically twice a day (morning and evening) for 14 days of treatment
Study: NCT01066520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel S ointment
Description: 2 g, 3 times daily topical during 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel S gel
Description: 2 g, 3 times daily topical during 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac gel
Description: 2 g, 3 times daily topical during 14 days
Study: NCT00370682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-DEN F17
Description: A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-DEN F-19
Description: A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: A single dose of 0.5 mL of the placebo sterile solution of buffer identical in appearance to vaccine)was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
Study: NCT03323073

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resting state fMRI
Description: One single fMRI which is used to characterize a uni or a bipolar major depressive episode (MDE).

Intervention type: OTHER
Group type: OTHER
Intervention: Resting state fMRI
Description: One single fMRI which is used to characterize a uni or a bipolar major depressive episode (MDE).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resting state fMRI
Description: One single fMRI which is used to characterize a uni or a bipolar major depressive episode (MDE).
Study: NCT03904212

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adipose tissue injection
Description: Injection with freshly harvested autologous adipose tissue

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: injection with saline
Study: NCT04539600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is a type of anti-PD-1 antibody that could enhance the immune system of the patient to fight cancer.
Study: NCT02124733

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic acid based photodynamic therapy
Description: The PDT treatments will be done in two stages. ALA (Levulan® Kerastick™) will be applied to the entire treatment area, and then the longer light exposure (lasting up to 1 hr) will be performed on one-half of the treatment area (Side A). After that, a shorter (16 min 40 sec) light exposure will be done on the other half (Side B).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic acid based photodynamic therapy
Description: The PDT treatments will be done in two stages. ALA (Levulan® Kerastick™) will be applied to the entire treatment area, and then the longer light exposure (lasting up to 1 hr) will be performed on one-half of the treatment area (Side A). After that, a shorter (16 min 40 sec) light exposure will be done on the other half (Side B).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic acid based photodynamic therapy
Description: The PDT treatments will be done in two stages. ALA (Levulan® Kerastick™) will be applied to the entire treatment area, and then the longer light exposure (lasting up to 1 hr) will be performed on one-half of the treatment area (Side A). After that, a shorter (16 min 40 sec) light exposure will be done on the other half (Side B).
Study: NCT00495729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Subjects will receive Simvastatin 10 mg tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Subjects will receive Simvastatin 10 mg tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Subjects will receive Simvastatin 10 mg tablets orally.
Study: NCT01983228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Condition
Description: Intervention participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
Study: NCT01622621

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sublobar Resection
Description: Undergo surgery which removes a sublobar resection of the lung

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sublobar Resection
Description: Undergo surgery which removes a sublobar resection of the lung

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: 54 Gy in 3 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: 54 Gy in 3 fractions
Study: NCT00531258

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Bilateral rTMS

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: sham rTMS
Study: NCT00646685

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical technique: duct-to-duct biliary reconstruction
Description: surgical reconstruction

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical technique: roux-en-y biliary reconstruction
Description: surgical reconstruction